Log In

 

Company Name : Takeda Pharmaceutical Company Limited

Tuesday, January 8, 2019 1:09PM IST (7:39AM GMT)

(BW)(TAKEDA-PHARMACEUTICAL)

Takeda Completes Acquisition of Shire, Becoming a Global, Values-Based, R&D-Driven Biopharmaceutical Leader


Osaka, Japan

  • 8 months from deal announcement to deal close
  • Strong shareholder support with high approval rates on Takeda (89.1%) and Shire (99.8%)
  • Integration planning well underway

Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced the completion of its acquisition of Shire plc (“Shire”), becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan.

 

Takeda now has an attractive, expanded geographic footprint and leading position in Japan and the U.S., bringing its highly-innovative medicines to approximately 80 countries/regions with dedicated employees worldwide. Takeda’s R&D efforts are focused on its four therapeutic areas of Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases, with targeted R&D investment also committed to Plasma-Derived Therapies (PDT) and Vaccines. Takeda's strengthened, highly innovative R&D engine enables the company to have a more global, robust and modality-diverse pipeline as well as to focus on breakthrough innovation. The combined annual revenue of the company, exceeding $30 billion USD, is mainly derived from the key business areas of Oncology, GI, Neuroscience, Rare Diseases and PDT.

 

“We are delighted that the acquisition was approved by an overwhelming majority of our shareholders at Takeda's extraordinary general meeting on December 5th, 2018. We are also pleased to have completed the acquisition several months earlier than expected, which was enabled through the hard work of our respective organizations and the smooth receipt of regulatory clearances,” said Christophe Weber, President and Chief Executive Officer of Takeda. “We appreciate the support of our employees, partners and shareholders throughout the process. This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey to deliver highly-innovative medicines to patients around the world with expanded scale and geographical footprint.”

 

Weber continued, “The execution of our integration begins today, and we are confident in our ability to execute a smooth integration under the leadership of our experienced and diverse Takeda Executive Team with a strong track record. The Operating Model we established in September last year has set a clear framework for our integration plans, and we have a highly skilled and dedicated integration team leading the process.”

 

In order to fund the acquisition, Takeda has secured permanent financing with highly competitive rates, resulting in an overall blended interest rate for Takeda's total debt of approximately 2.3%. The company is confident that it will retain its investment grade credit rating and return to a net debt to EBITDA ratio of 2.0x or less within three to five years following completion.

 

Weber will present at the J.P. Morgan Healthcare Conference at 3:30 p.m. PST on January 8, 2019.

 

About Takeda Pharmaceutical Company Limited

 

Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Investor Relations Contact:
Takashi Okubo
takeda.ir.contact@takeda.com
+81 3 3278 2306

Media Inquiries:
Tsuyoshi Tada (Outside of Japan)
Tsuyoshi.Tada@takeda.com
+1 617 551 2933

Kazumi Kobayashi (Japan)
Kazumi.kobayashi@takeda.com
+81 3 3278 2095


More News from Takeda Pharmaceutical Company Limited

03/01/2019 6:47PM

Takeda Announces Multiple Cell Therapy Collaborations to Advance the Company’s Novel Immuno-Oncology Portfolio

Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) today announced new research collaborations in immuno-oncology (I-O), an area of key strategic focus for the company. Through these ...

20/12/2018 12:25PM

Takeda Announces Listing of American Depositary Shares on the New York Stock Exchange

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Takeda ...

17/12/2018 3:10PM

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD

– If Authorized in Europe, ADCETRIS in Combination with AVD (Adriamycin, Vinblastine and Dacarbazine) Will Be the First New Treatment Regimen Available for Adult Patients with Previously Untreated CD30+ Stage IV ...

Similar News

18/01/2019 5:00PM Image

In Partnership With the First Lady of Ghana, Merck Foundation Calls for Applications for Media Recognition Awards 2018 to Eliminate Infertility Stigma

Merck Foundation, the philanthropic arm of Merck KGaA Germany in partnership with H.E. REBECCA NAA OKAIKOR AKUFO-ADDO, The First Lady of Ghana and Ambassador of Merck More Than a Mother announces the opening of the ...

No Image

18/01/2019 2:07PM

Philips Launches Advanced Imaging Systems Solutions in India

Royal Philips a global leader in health technology, today unveiled its latest Imaging Systems range with solutions including the Next MR Wave (Ingenia Ambition, Ingenia Elition), Epiq Elite Ultrasound System, ...